ArticleDrug and alcohol dependence2025
Predictors of Medicaid managed care plan performance on opioid use disorder treatment quality metrics.
Article in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements.The Milbank quarterly · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionMedicaid managed care plans (MCPs) and states play essential roles in supporting access to high-quality opioid use disorder (OUD) treatment services. This study aimed to identify MCP and state-level policies associated with better plan performance on indicators of quality OUD treatment.
methodsPublicly available data on Medicaid MCPs' profit status, behavioral health contracting arrangements, market share, buprenorphine prior authorization and quantity limit policies and state Medicaid policies were linked with plan-level measures of OUD treatment quality from the National Committee on Quality Assurance (n = 107). Regression analyses were used to examine associations between Medicaid MCP characteristics, MCP buprenorphine policies, and features of the state policy environment with plan-level rates of OUD treatment initiation and engagement.
resultsThe average OUD treatment initiation rate was 59.6 % and engagement was 30.9 %. MCPs with large market share had initiation and engagement rates 4.66 and 4.54 percentage points lower, respectively, than plans with small market share. Plans operating in states with 1115 SUD waivers had initiation and engagement rates 7.75 and 8.55 percentage points higher, respectively, than plans in states without waivers. Engagement rates among plans that required prior authorization for buprenorphine were 4.53 percentage points lower than plans without this restriction.
conclusionsFindings suggest state and MCP policies are important pathways to improve initial and sustained OUD treatment. Further research into these relationships is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.